ID
12144
Description
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients NCT00090051 Roche BO17072
Keywords
Versions (2)
- 9/30/15 9/30/15 -
- 10/28/15 10/28/15 -
Uploaded on
September 30, 2015
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0 Legacy
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
CLL Adverse Event NCT00090051 BO17072
Adverse event or intercurrent illness Chronic Lymphocytic Leukemia NCT00090051 BO17072
Description
Adverse event treatments
Alias
- UMLS CUI-1
- C2981656
Description
treatment name
Data type
text
Alias
- UMLS CUI [1,1]
- C0087111
- UMLS CUI [1,2]
- C0027365
Description
Treatment Start Date
Data type
date
Measurement units
- dd/mm/yy
Alias
- UMLS CUI [1]
- C3173309
Description
Treatment End Date
Data type
date
Measurement units
- dd/mm/yy
Alias
- UMLS CUI [1]
- C1531784
Description
Treatment Ongoing at final contact
Data type
boolean
Similar models
Adverse event or intercurrent illness Chronic Lymphocytic Leukemia NCT00090051 BO17072
C2699488 (UMLS CUI [1,2])
C0027365 (UMLS CUI [1,2])